Sorbitol

Summary

Sorbitol (CHEMBL1682) is an approved small-molecule sweetening agent (ATC V04CC01); indicated across 9 conditions including constipation disorder and charcot-marie-tooth disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V04CC01 (+3 more)
• Indications: 9 conditions
• Clinical trials: 130
• Chemistry: 182.17 Da · C6H14O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1682
Name	Sorbitol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5780
ChEBI	CHEBI:17924
ATC	V04CC01, B05CX02, A06AD18, A06AG07
Molecular formula	C6H14O6
Molecular weight	182.17
InChIKey	FBPFZTCFMRRESA-JGWLITMVSA-N

SMILES: C([C@H]([C@H]([C@@H]([C@H](CO)O)O)O)O)O

IUPAC name: (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol

ChEBI definition: The D-enantiomer of glucitol (also known as D-sorbitol).

Pharmacological roles (ChEBI): sweetening agent, laxative, cathartic.

Other ChEBI roles (chemical / environmental): metabolite, human metabolite, food humectant, Saccharomyces cerevisiae metabolite, Escherichia coli metabolite, mouse metabolite.

Also known as: 7B5697N, D-glucitol, D-glucitol syrup, D-sorbitol, E 420, E-420(i), FEMA NO. 3029, Glucitol, d-, Ins no.420(i), Ins-420(i), Isomalt impurity

Patent coverage: 333,246 distinct patent families (1,012,877 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
constipation disorder	4	MONDO:0002203	HP:0002019
Charcot-Marie-Tooth disease	3	MONDO:0015626	MONDO:0015626
metabolic dysfunction-associated steatotic liver disease	2	MONDO:0013209	EFO:0003095
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
injury	2	MONDO:0021178	EFO:0000546
osteoarthritis, knee	2	MONDO:0005416	EFO:0004616
chronic myeloid leukemia	1	MONDO:0011996	EFO:0000339
bacterial infectious disease	1	MONDO:0005113	EFO:0000771

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 130.

Phase distribution

Phase	Trials
Not specified	38
PHASE3	22
PHASE2	20
PHASE1/PHASE2	15
PHASE4	14
PHASE2/PHASE3	9
PHASE1	9
EARLY_PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06841406	PHASE4	RECRUITING	Budesonide as a Treatment for Functional Dyspepsia
NCT06884657	PHASE4	RECRUITING	Effect of Mannitol on Propofol Level
NCT00426192	PHASE4	UNKNOWN	Effects of Hemofiltration and Mannitol Treatment on Cardiopulmonary-Bypass Induced Immunosuppression
NCT00638677	PHASE4	COMPLETED	Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier
NCT00677664	PHASE4	UNKNOWN	Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation
NCT01642745	PHASE4	COMPLETED	Mannitol (Aridol) and Methacholine (Provocholine) Responsiveness
NCT01879605	PHASE4	COMPLETED	Study About Effect of Preoperative Bowel Preparation Versus no Bowel Preparation Before Spinal Surgery
NCT02091180	PHASE4	COMPLETED	Mannitol Improves Cerebral Oxygen Saturation
NCT02386449	PHASE4	COMPLETED	A Study Comparing Picoprep With Mannitol and Bisacodyl for Colon Cleansing in Preparation for Colonoscopy
NCT02634073	PHASE4	COMPLETED	A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers
NCT02677623	PHASE4	COMPLETED	Evaluation of Ureteral Patency in the Post-indigo Carmine Era
NCT02760862	PHASE4	COMPLETED	Comparative Study Between Hydrocortisone and Mannitol in Treatment of Postdural Puncture Headache
NCT03573999	PHASE4	COMPLETED	Effect of Mannitol 20% Versus Hypertonic Saline 7.5% in Brain Metabolism and Oxygenation
NCT04534465	PHASE4	COMPLETED	Study to Gather Information on the Acceptability of a New Flavor System With Increasing Levels of 2, 4, 6 g or Higher of Mannitol for PEG 3350 in Subjects Having Infrequent Bowel Movements.
NCT04217421	PHASE3	RECRUITING	Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass
NCT06473779	PHASE3	ACTIVE_NOT_RECRUITING	Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06826079	PHASE2/PHASE3	RECRUITING	Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
NCT06914310	PHASE2/PHASE3	NOT_YET_RECRUITING	Memantine as an Additive Therapy in Patients With Traumatic Brain Injury
NCT00113854	PHASE3	UNKNOWN	Mannitol as Adjunct Therapy for Childhood Cerebral Malaria
NCT00189007	PHASE3	UNKNOWN	Antenatal Allopurinol During Fetal Hypoxia
NCT00277537	PHASE3	COMPLETED	Safety and Efficacy of Bronchitol in Bronchiectasis
NCT00319345	PHASE2/PHASE3	TERMINATED	Sodium-Lactate and Traumatic Brain Injury
NCT00446680	PHASE3	COMPLETED	Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study
NCT00630812	PHASE3	COMPLETED	Long Term Administration of Inhaled Mannitol in Cystic Fibrosis
NCT00669331	PHASE3	COMPLETED	Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis
NCT01028339	PHASE3	TERMINATED	Mannitol vs HS to Treat ICHT After Severe TBI : Comparison on PtiO2 and Microdialysis Values
NCT01111682	PHASE3	TERMINATED	Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure
NCT01142505	PHASE3	COMPLETED	Wheeze and Intermittent Treatment
NCT01606787	PHASE3	COMPLETED	Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes
NCT02134353	PHASE3	COMPLETED	A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects
NCT02196142	PHASE3	COMPLETED	Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence
NCT02570971	PHASE3	UNKNOWN	Mannitol Versus Supportive Care in Ciguatera Fish Poisoning
NCT02705573	PHASE3	COMPLETED	Effects of Mannitol on Delayed Graft Function After Cadaveric Renal Transplantation
NCT03162653	PHASE3	UNKNOWN	Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome
NCT03505489	PHASE3	COMPLETED	The Effect of Deep Inhalation on Mannitol Responsiveness
NCT04251689	PHASE2/PHASE3	COMPLETED	The Effect of Intravenous Mannitol Plus Saline on the Prevention of Cisplatin-induced Nephrotoxicity: A Randomized, Double-blind, Placebo Controlled Trial
NCT04385264	PHASE2/PHASE3	WITHDRAWN	#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19
NCT04394143	PHASE2/PHASE3	COMPLETED	Effect of AD128 to Treat Obstructive Sleep Apnea
NCT04428372	PHASE2/PHASE3	COMPLETED	MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)
NCT04488874	PHASE3	COMPLETED	Sodium Lactate and Brain Relaxation (LSD)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).